View of Long-term Upadacitinib Safety in Moderate-to-Severe Atopic Dermatitis up to 7 Years: an Integrated Analysis with Over 9600 Patient-Years of exposure

Return to Article Details Long-term Upadacitinib Safety in Moderate-to-Severe Atopic Dermatitis up to 7 Years: an Integrated Analysis with Over 9600 Patient-Years of exposure Download Download PDF